WO2007084914A3 - Pyrimidines substituees par un groupe phenoxy en tant qu'antagonistes des recepteurs d’adenosine - Google Patents

Pyrimidines substituees par un groupe phenoxy en tant qu'antagonistes des recepteurs d’adenosine Download PDF

Info

Publication number
WO2007084914A3
WO2007084914A3 PCT/US2007/060632 US2007060632W WO2007084914A3 WO 2007084914 A3 WO2007084914 A3 WO 2007084914A3 US 2007060632 W US2007060632 W US 2007060632W WO 2007084914 A3 WO2007084914 A3 WO 2007084914A3
Authority
WO
WIPO (PCT)
Prior art keywords
phenoxy
receptor antagonists
adenosine receptor
substituted pyrimidines
pyrimidines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/060632
Other languages
English (en)
Other versions
WO2007084914A2 (fr
Inventor
Deborah Slee
Xiaohu Zhang
Jaimie K Rueter
Emily Lin
Crespo Maria Isabel Crespo
Palomino Laria Julio Ce Castro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Almirall SA
Neurocrine Biosciences Inc
Original Assignee
Laboratorios Almirall SA
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Almirall SA, Neurocrine Biosciences Inc filed Critical Laboratorios Almirall SA
Priority to EP07718002A priority Critical patent/EP1976851A2/fr
Publication of WO2007084914A2 publication Critical patent/WO2007084914A2/fr
Publication of WO2007084914A3 publication Critical patent/WO2007084914A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des composés répondant à la formule (I), comprenant des sels pharmaceutiquement acceptables, des esters, des solvates, des stéréoisomères et des promédicaments de ceux-ci, dans laquelle R1, R2, R3, R4, R5, X, m et n sont tels que définis dans le présent document. La présente invention concerne également des compositions pharmaceutiques contenant un composé répondant à la formule (I), ainsi que des procédés se rapportant à l’utilisation de ceux-ci.
PCT/US2007/060632 2006-01-17 2007-01-17 Pyrimidines substituees par un groupe phenoxy en tant qu'antagonistes des recepteurs d’adenosine Ceased WO2007084914A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP07718002A EP1976851A2 (fr) 2006-01-17 2007-01-17 Pyrimidines substituees par un groupe phenoxy en tant qu'antagonistes des recepteurs d adenosine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75969206P 2006-01-17 2006-01-17
US60/759,692 2006-01-17

Publications (2)

Publication Number Publication Date
WO2007084914A2 WO2007084914A2 (fr) 2007-07-26
WO2007084914A3 true WO2007084914A3 (fr) 2007-10-04

Family

ID=38169639

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/060632 Ceased WO2007084914A2 (fr) 2006-01-17 2007-01-17 Pyrimidines substituees par un groupe phenoxy en tant qu'antagonistes des recepteurs d’adenosine

Country Status (2)

Country Link
EP (1) EP1976851A2 (fr)
WO (1) WO2007084914A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9447071B2 (en) 2014-02-07 2016-09-20 Global Blood Therapeutics, Inc. Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101903385B (zh) * 2007-12-21 2013-11-06 帕劳制药股份有限公司 作为组胺h4受体拮抗剂的4-氨基嘧啶衍生物
HK1203412A1 (en) 2011-12-28 2015-10-30 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
WO2013102142A1 (fr) 2011-12-28 2013-07-04 Global Blood Therapeutics, Inc. Composés benzaldéhyde substitués et procédés d'utilisation de ceux-ci dans l'augmentation de l'oxygénation des tissus
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
SG10201802911RA (en) 2013-03-15 2018-05-30 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
AP2015008718A0 (en) 2013-03-15 2015-09-30 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
WO2014145040A1 (fr) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Composés aldéhydes substitués et leurs procédés d'utilisation pour accroître l'oxygénation tissulaire
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
EP3919056B1 (fr) 2013-03-15 2024-08-28 Global Blood Therapeutics, Inc. Composés et leurs utilisations pour la modulation de l'hémoglobine
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
WO2015031285A1 (fr) * 2013-08-27 2015-03-05 Global Blood Therapeutics, Inc. Sels d'ansolvats 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde cristallins
EA202092627A1 (ru) 2013-11-18 2021-09-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
WO2015116061A1 (fr) * 2014-01-29 2015-08-06 Global Blood Therapeutics, Inc. Produits d'addition 1:1 d'hémoglobine s
US9248199B2 (en) 2014-01-29 2016-02-02 Global Blood Therapeutics, Inc. 1:1 adducts of sickle hemoglobin
US11020382B2 (en) 2015-12-04 2021-06-01 Global Blood Therapeutics, Inc. Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
TWI825524B (zh) 2016-05-12 2023-12-11 美商全球血液治療公司 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法
TW202332423A (zh) 2016-10-12 2023-08-16 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
EP3860975B1 (fr) 2018-10-01 2023-10-18 Global Blood Therapeutics, Inc. Modulateurs de l'hémoglobine pour le traitement de la drépanocytose

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005058883A1 (fr) * 2003-12-15 2005-06-30 Almirall Prodesfarma Ag 2, 6-bisheteroaryl-4-aminopyrimidines utilisees en tant qu'antagonistes des recepteurs de l'adenosine
WO2006110884A2 (fr) * 2005-04-11 2006-10-19 Neurocrine Biosciences, Inc. Pyrimidines substituees utilisees comme antagonistes du recepteur d'adenosine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005058883A1 (fr) * 2003-12-15 2005-06-30 Almirall Prodesfarma Ag 2, 6-bisheteroaryl-4-aminopyrimidines utilisees en tant qu'antagonistes des recepteurs de l'adenosine
WO2006110884A2 (fr) * 2005-04-11 2006-10-19 Neurocrine Biosciences, Inc. Pyrimidines substituees utilisees comme antagonistes du recepteur d'adenosine

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9447071B2 (en) 2014-02-07 2016-09-20 Global Blood Therapeutics, Inc. Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde

Also Published As

Publication number Publication date
WO2007084914A2 (fr) 2007-07-26
EP1976851A2 (fr) 2008-10-08

Similar Documents

Publication Publication Date Title
WO2007084914A3 (fr) Pyrimidines substituees par un groupe phenoxy en tant qu'antagonistes des recepteurs d’adenosine
WO2007115077A3 (fr) Composés de benzimidazole bicyclique et leur utilisation comme potentialisateurs du récepteur métabotropique du glutamate
TW200728307A (en) Novel spirochromanone derivatives
WO2008097459A3 (fr) Agents anti hypertension à double action
TW200740758A (en) Benzoquinazoline derivatives
WO2008133896A3 (fr) Agents antihypertensifs à double action
WO2007135527A3 (fr) Composés de benzimidazolyle
MX2007005694A (es) Nuevos derivados de betulina, preparacion y uso de los mismos.
WO2007109578A3 (fr) Gamma lactames substitues en tant qu'agents therapeutiques
WO2008096231A8 (fr) Agents antiparasitaires
MX2009008540A (es) Inhibidores de virus de hepatitis c macrociclicos sustituidos con pirimidina.
WO2008120725A1 (fr) Nouveau dérivé de pyrrolinone et composition médicale le contenant
WO2008096829A1 (fr) Composés tricycliques
WO2007146856A3 (fr) Gamma lactames substitués utilisés en tant qu'agents thérapeutiques
MX2009004780A (es) Derivados de quiniclidina de acido (hetero) arilcicloheptano carboxilico como antagonistas del receptor muscarinico.
TN2009000287A1 (en) Cyclized derivatives as eg-5inhibitors
WO2007147771A3 (fr) Dérivés tétraline et indane et leurs utilisations
WO2007031933A3 (fr) Composition pharmaceutique stable a pyrimidine-sulfamide
WO2006113509A3 (fr) Analogues de quinobenzoxazines et procedes d'utilisation de ceux-ci
WO2008116185A3 (fr) Pyrimidines substituées utilisées comme antagonistes des récepteurs de l'adénosine
WO2008000692A3 (fr) Dérivés de pyrimidine et de quinazoline
WO2008052088A8 (fr) Dérivés de chromane, synthèse de ceux-ci et leurs intermédiaires
WO2007017728A3 (fr) Nouveaux composes heterocycliques
TW200728298A (en) Thiophene compounds and thrombopoietin receptor activators
WO2006110884A8 (fr) Pyrimidines substituees utilisees comme antagonistes du recepteur d'adenosine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007718002

Country of ref document: EP